Krka, d. d. Share Price

Equities

KRKG

SI0031102120

Pharmaceuticals

End-of-day quote Ljubljana S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
125.5 EUR +0.40% Intraday chart for Krka, d. d. -0.40% +14.09%

Financials

Sales 2024 * 1.87B 2B 160B Sales 2025 * 1.96B 2.09B 167B Capitalization 3.87B 4.14B 331B
Net income 2024 * 343M 367M 29.37B Net income 2025 * 359M 384M 30.74B EV / Sales 2024 * 1.79 x
Net cash position 2024 * 515M 550M 44.08B Net cash position 2025 * 543M 581M 46.54B EV / Sales 2025 * 1.7 x
P/E ratio 2024 *
11.6 x
P/E ratio 2025 *
11.1 x
Employees 10,284
Yield 2024 *
5.56%
Yield 2025 *
5.83%
Free-Float 72.38%
More Fundamentals * Assessed data
Dynamic Chart
Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on July 20, 2023. CI
Krka, d. d. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd CI
Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on August 3, 2020. CI
Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on July 20, 2023. CI
Krka, d. d. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Krka, d. d. commences an Equity Buyback Plan for 1,452,216 shares, representing 4.69% of its issued share capital, under the authorization approved on July 6, 2023. CI
Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on August 3, 2020. CI
Krka, d. d. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Krka, d. d.'s Equity Buyback announced on August 3, 2020, has expired with 593,278 shares, representing 1.9% for ?54.83 million. CI
Krka, d. d. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on August 3, 2020. CI
Krka, d. d. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Tranche Update on Krka, d. d.'s Equity Buyback Plan announced on August 3, 2020. CI
Krka Reportedly Eyes Promoter Stake in Unichem Laboratories CI
More news
1 day+0.40%
1 week-0.40%
Current month-2.33%
1 month-2.71%
3 months+9.61%
6 months+18.96%
Current year+14.09%
More quotes
1 week
123.50
Extreme 123.5
128.00
1 month
122.00
Extreme 122
129.50
Current year
110.00
Extreme 110
131.00
1 year
100.00
Extreme 100
131.00
3 years
80.00
Extreme 80
131.00
5 years
54.00
Extreme 54
131.00
10 years
48.01
Extreme 48.01
131.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 31/12/81
Director of Finance/CFO - 31/12/96
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 57 31/12/18
Director/Board Member 57 31/12/83
Director/Board Member 57 31/12/89
More insiders
Date Price Change Volume
26/04/24 125.5 +0.40% 22,811
25/04/24 125 +0.40% 7,186
24/04/24 124.5 -0.40% 3,971
23/04/24 125 0.00% 4,284
22/04/24 125 -0.79% 4,840

End-of-day quote Ljubljana S.E., April 25, 2024

More quotes
Krka dd Novo Mesto is a Slovenia-based company engaged in the production of pharmaceutical preparations. The Company operates through four segments: Prescription Pharmaceuticals that includes medicines for the treatment of cardiovascular diseases, alimentary tract and metabolism and drugs for diseases of the central nervous system, among others; Non-prescription Products, providing vitamins and minerals, cough and cold products, analgesics, sore throat products, among others; Animal Health Products, which offers general anti-infectives and antiparasitics for animals; Health Resort and Tourist Services consisting of Spa resorts in Smarjeske Toplice, Dolenjske Toplice, Strunjan, Novo Mesto and Otocec. Krka dd Novo Mesto is a controlling company of the Krka Group that includes two subsidiaries in Slovenia, Terme Krka doo and Farma GRS doo, and over 20 subsidiaries abroad in such countries as Croatia, Germany, Sweden, Poland, Spain, United States, Ireland, among others.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
125.5 EUR
Average target price
133.6 EUR
Spread / Average Target
+6.49%
Consensus

Annual profits - Rate of surprise